个人简述:

徐寒梅，女，中国药科大学生命科学与技术学院教授，博士生导师，海洋药学教研室主任。自2002年于南京大学国家医药生物技术重点实验室进行博士后研究期间，开始抗肿瘤蛋白质及多肽的研究。2004年底到中国药科大学工作，继续从事抗肿瘤多肽的研究，设计合成了抗肿瘤多肽安替安吉肽,AP25，EDSM等具有自主知识产权的多肽，其中安替安吉肽于2013年9月获得一类新药临床批件。近五年在国内外发表学术文章50余篇，SCI20余篇；主编及参编论著各一部，主编教材《海洋制药学》一部；申请发明专利共25项(其中国际专利5项)。近五年以来，先后主持了：国家自然科学基金，国家“863”高科技发展计划，国家“十一五”、“十二五”“重大新药创制”科技重大专项，江苏省校企合作前瞻性研究等项目，近五年带领课题组（包括南京大学、武汉大学、广州药学院、医药企业）获得国家资助3800余万元。因与企业合作抗肿瘤多肽研究的表现获得内蒙古自治区“杰出创新引进人才”奖，“草原英才”；近五年先后获得江苏省“青蓝工程”优秀骨干教师，中青年学术带头人，南京市领军人才等奖励和称号；因为产学研合作的表现被内蒙古自治区政府聘为科技特派员; 被教育部“蓝火工程”聘为泰州市科技特派员。

科研工作:

近五年以第一作者或通讯作者发表的SCI论文文章：1. Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang Jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei*. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. Journal of Materials Chemistry B, 2014, 2:800-813.2. Jialiang Hu, Ming Yan, ChunyanPu, Jingjing Wang, Philippe E. Van den steen, GhislainOpdenakker, HanmeiXu*. Chemically synthesized matrix metalloproteinase- and angiogenesis-inhibiting peptides as anticancer agents. Anti-cancer Reagents ME. 2014 Mar14(3):483-94.3. Dongqing Yuan , Hong Shen , Songtao Yuan , Xiaoyi Liu, Xin Xia, Ping Xie , Weiguang Li , Jialiang Hu , Qinghuai Liu , Hanmei Xu*. Pharmacokinetics of HM-3 after intravitreal administration in mice. Current Eye Research. 2014, Feb 21,online.4. Li Yongbing, Xu Hanmei*, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein Pept Lett. 2012 Sep 4. [Epub ahead of print]5. Chunyan Pu，Hanmei Xu*, Jialiang Hu, Zheng Heng, Xiaofeng Huang, Zhang Chi Yongjing Yang, Yongbing Li, RGD position has effect on anti-angiogenic activity of RGD modified endostation derived synthetic polypeptides. Anti-cancer drugs. 2012, 12: 788-8026. Li Pan1, Jialiang Hu1, Wenjing Wang1, Xiaojuan Zhang1, Jin Wei1, Zhendong Liu1, Yihua Zhang2* and Hanmei Xu1*. Molecular Mechanisms of (R,R) ZX-5 on NO Synthesis and Its Anti-Angiogenic Effect. International Journal of Molecular Sciences. 2012, 13, 2717-2726.7. Liu Zhendong, Li Weiguang, Xu Hanmei*, Huang Xiaofeng, Pan Li, Ren Yinling, Yang Yongjing, Li Yongbing, Pu Chunyan, Zhang Chi. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated anti-tumor polypeptide. Current Pharmaceutical Design. 2012,18(12):1655-1662.8.Guoqiu Wu, Xuepeng Deng，Pengpeng Wu, Zilong Shen, Hanmei Xu*, Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice. Peptides 2012, 36 ( 1 ): 109-13.9. Hanmei Xu*, Li Pan, Yinling Ren , et al.An RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment. Bioconjugate Chem., 2011, 22 (7): 1386–1393.10. Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu*, In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG). Int. J. Mol. Sci. 2011, 12(4), 2650-2663.11. Guoqiu Wu,Xuepeng Deng , Hanmei Xu*, et al. Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli. Appl Microbiol Biotechnol. 2011, 92(1):85-93.